180 Life Sciences Corp. Financial Statements — ATNF Stock

Income Statement	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
Sales/Revenue/Turnover	- -	- -	- -	- -	- -
+ Sales & Services Revenue	- -	- -	- -	- -	- -
- Cost of Revenue	- -	- -	- -	- -	- -
+ Cost of Goods & Services	- -	- -	- -	- -	- -
Gross Profit	- -	- -	- -	- -	- -
+ Other Operating Income	- -	- -	- -	- -	- -
- Operating Expenses	21	6	16	18	13
+ Selling, General & Admin	19	3	12	15	11
+ Research & Development	2	2	4	2	3
+ Other Operating Expense	- -	- -	- -	- -	- -
Operating Income (Loss)	-21	-6	-16	-18	-13
- Non-Operating (Income) Loss	5	5	5	22	9
+ Interest Expense, Net	- -	1	- -	- -	- -
+ Interest Expense	- -	1	- -	- -	- -
- Interest Income	- -	- -	- -	- -	- -
+ Other Non-Op (Income) Loss	4	4	5	22	9
Pretax Income	-25	-11	-20	-40	-22
- Income Tax Expense (Benefit)	- -	- -	- -	-1	-2
- (Income) Loss from Affiliates	- -	- -	- -	- -	- -
Income (Loss) from Cont Ops	-25	-11	-20	-39	-20
- Net Extraordinary Losses (Gains)	- -	- -	- -	- -	- -
+ Discontinued Operations	- -	- -	- -	- -	- -
+ Extraord. & Accounting Changes	- -	- -	- -	- -	- -
Income (Loss) Incl. MI	-25	-11	-20	-39	-20
- Minority Interest	- -	- -	- -	- -	- -
Net Income, GAAP	-25	-11	-20	-39	-20
- Preferred Dividends	- -	1	- -	- -	- -
- Other Adjustments	- -	- -	- -	- -	- -
Net Income Avail to Common, GAAP	-25	-12	-20	-39	-20
Basic Weighted Avg Shares	- -	- -	- -	- -	- -
Basic EPS, GAAP	-874.45	-251.33	-246.32	-387.19	-52.59
Basic EPS from Cont Ops	-874.45	-227.83	-246.32	-387.19	-52.59
Diluted Weighted Avg Shares	- -	- -	- -	- -	- -
Diluted EPS, GAAP	-874.45	-251.33	-246.32	-387.19	-52.59
Diluted EPS from Cont Ops	-874.45	-227.83	-246.32	-387.19	-52.59
EBITDA	-21	-6	-16	-18	-13
EBITDA Margin (%)	- -	- -	- -	- -	- -
EBITA	-21	-6	-16	-18	-13
EBIT	-21	-6	-16	-18	-13
Gross Margin (%)	- -	- -	- -	- -	- -
Operating Margin (%)	- -	- -	- -	- -	- -
Profit Margin (%)	- -	- -	- -	- -	- -
Sales per Employee	- -	- -	- -	- -	- -
Dividend per Share	- -	- -	- -	- -	- -
Depreciation Expense	- -	- -	- -	- -	- -

Balance Sheet	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
Total Current Assets	1	4	11	9	4
+ Cash, Cash Equivalents & STI	- -	2	8	7	2
+ Cash & Cash Equivalents	- -	2	8	7	2
+ ST Investments	- -	- -	- -	- -	- -
+ Accounts & Notes Receiv	- -	1	1	1	- -
+ Accounts Receivable, Net	- -	- -	- -	- -	- -
+ Notes Receivable, Net	- -	- -	- -	- -	- -
+ Loans Receivable, Net	- -	- -	- -	- -	- -
+ Other Receivable, Net	- -	1	1	1	- -
+ Inventories	- -	- -	- -	- -	- -
+ Raw Materials	- -	- -	- -	- -	- -
+ Work In Process	- -	- -	- -	- -	- -
+ Finished Goods	- -	- -	- -	- -	- -
+ Inventory Adjustments	- -	- -	- -	- -	- -
+ Other Inventory	- -	- -	- -	- -	- -
+ Other ST Assets	- -	1	2	1	1
+ Misc ST Assets	- -	- -	- -	- -	- -
+ Prepaid Expenses	- -	- -	- -	- -	- -
+ ST Derivative & Hedging Assets	- -	- -	- -	- -	- -
+ ST Assets Held-for-Sale	- -	- -	- -	- -	- -
+ ST Deferred Tax Assets	- -	- -	- -	- -	- -
Total Noncurrent Assets	51	52	52	11	2
+ Property, Plant & Equip, Net	- -	- -	- -	- -	- -
+ Property, Plant & Equip	- -	- -	- -	- -	- -
- Accumulated Depreciation	- -	- -	- -	- -	- -
+ LT Investments & Receivables	- -	- -	- -	- -	- -
+ LT Investments	- -	- -	- -	- -	- -
+ LT Receivables	- -	- -	- -	- -	- -
+ Other LT Assets	51	52	52	11	2
+ Total Intangible Assets	51	52	52	11	2
+ Goodwill	36	37	37	- -	- -
+ Other Intangible Assets	15	15	15	11	2
+ LT Deferred Tax Assets	- -	- -	- -	- -	- -
+ LT Derivative & Hedging Assets	- -	- -	- -	- -	- -
+ Misc LT Assets	- -	- -	- -	- -	- -
Total Assets	52	56	63	20	5
+ Payables & Accruals	6	12	2	3	3
+ Accounts Payable	4	9	1	2	2
+ Accrued Taxes	- -	- -	- -	- -	- -
+ Interest & Dividends Payable	- -	- -	- -	- -	- -
+ Other Payables & Accruals	2	4	1	1	2
+ ST Debt	4	4	2	1	1
+ ST Borrowings	4	4	2	1	1
+ ST Finance Leases	- -	- -	- -	- -	- -
+ Other ST Liabilities	- -	5	16	2	1
+ Deferred Revenue	- -	- -	- -	- -	- -
+ Derivatives & Hedging	- -	- -	- -	- -	- -
+ Deferred Tax Liabilities	- -	- -	- -	- -	- -
+ Misc ST Liabilities	- -	5	16	2	1
Total Current Liabilities	10	21	20	6	5
+ LT Debt	- -	- -	- -	- -	- -
+ LT Borrowings	- -	- -	- -	- -	- -
+ LT Finance Leases	- -	- -	- -	- -	- -
+ Other LT Liabilities	4	4	4	3	- -
+ Accrued Liabilities	4	4	4	3	- -
+ Pension Liabilities	- -	- -	- -	- -	- -
+ Deferred Revenue	- -	- -	- -	- -	- -
+ Deferred Tax Liabilities	- -	- -	- -	- -	- -
+ Derivatives & Hedging	- -	- -	- -	- -	- -
+ Misc LT Liabilities	- -	- -	- -	- -	- -
Total Noncurrent Liabilities	4	4	4	3	- -
Total Liabilities	13	25	23	8	5
+ Preferred Equity and Hybrid Capital	- -	- -	- -	- -	- -
+ Share Capital & APIC	76	78	107	122	130
+ Common Stock	- -	- -	- -	- -	- -
+ Additional Paid in Capital	76	78	107	122	130
- Treasury Stock	- -	- -	- -	- -	- -
+ Retained Earnings	-37	-48	-69	-107	-127
+ Other Equity	- -	1	1	-3	-3
Equity Before Minority Interest	39	30	39	11	- -
+ Minority/Non Controlling Interest	- -	- -	- -	- -	- -
Total Equity	39	30	39	11	- -
Total Liabilities & Equity	52	56	63	20	5
Shares Outstanding	- -	- -	- -	- -	1
Capital Leases - Total	- -	- -	- -	- -	- -
Net Debt	3	2	-6	-6	-1
Net Debt to Equity	8.93	5.52	-15.94	-49.63	721.61
Tangible Common Equity Ratio	-1,558.8	-528.81	-108.83	6.97	-48
Current Ratio	0.08	0.19	0.57	1.58	0.72
Cash Conversion Cycle	- -	- -	- -	- -	- -
Number of Employees	- -	- -	- -	- -	- -

Cash Flow Statement	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
+ Net Income	-25	-11	-20	-39	-20
+ Depreciation & Amortization	- -	- -	- -	- -	- -
+ Non-Cash Items	19	5	10	24	9
+ Stock-Based Compensation	13	1	5	3	2
+ Deferred Income Taxes	- -	- -	- -	-1	-2
+ Asset Impairment Charge	1	-2	- -	37	9
+ Other Non-Cash Adj	5	5	4	-15	- -
+ Chg in Non-Cash Work Cap	3	2	-9	3	- -
+ (Inc) Dec in Accts Receiv	- -	- -	- -	- -	- -
+ (Inc) Dec in Inventories	- -	- -	- -	- -	- -
+ (Inc) Dec in Prepaid Assets	1	- -	-1	1	- -
+ Inc (Dec) in Accts Payable	3	3	-7	2	- -
+ Inc (Dec) in Other	-1	- -	- -	- -	- -
+ Net Cash From Disc Ops	- -	- -	- -	- -	- -
Cash from Operating Activities	-3	-4	-19	-12	-11
+ Change in Fixed & Intang	- -	- -	- -	- -	- -
+ Disp in Fixed & Intang	- -	- -	- -	- -	- -
+ Disp of Fixed Prod Assets	- -	- -	- -	- -	- -
+ Disp of Intangible Assets	- -	- -	- -	- -	- -
+ Acq of Fixed & Intang	- -	- -	- -	- -	- -
+ Acq of Fixed Prod Assets	- -	- -	- -	- -	- -
+ Acq of Intangible Assets	- -	- -	- -	- -	- -
+ Net Change in LT Investment	- -	- -	- -	- -	- -
+ Dec in LT Investment	- -	- -	- -	- -	- -
+ Inc in LT Investment	- -	- -	- -	- -	- -
+ Net Cash From Acq & Div	- -	3	- -	- -	- -
+ Cash from Divestitures	- -	3	- -	- -	- -
+ Cash for Acq of Subs	- -	- -	- -	- -	- -
+ Cash for JVs	- -	- -	- -	- -	- -
+ Other Investing Activities	-1	11	- -	- -	- -
+ Net Cash From Disc Ops	- -	- -	- -	- -	- -
Cash from Investing Activities	-1	14	- -	- -	- -
+ Dividends Paid	- -	- -	- -	- -	- -
+ Net Cash From Debt	3	- -	1	- -	- -
+ Cash From Debt	3	- -	2	2	1
+ Repayments of Debt	- -	- -	-1	-2	-1
+ Cash (Repurchase) of Equity	1	-9	27	11	6
+ Increase in Capital Stock	1	- -	27	12	6
+ Decrease in Capital Stock	- -	-9	- -	-1	- -
+ Other Financing Activities	- -	- -	-2	-1	- -
+ Net Cash From Disc Ops	- -	- -	- -	- -	- -
Cash from Financing Activities	4	-9	25	11	6
Effect of Foreign Exchange Rates	- -	- -	- -	- -	- -
Net Changes in Cash	- -	2	6	-1	-5
Capital Expenditures	- -	- -	- -	- -	- -
EBITDA	-21	-6	-16	-18	-13
EBITDA Margin (%)	- -	- -	- -	- -	- -
Net Cash Paid for Acquisitions	- -	-3	- -	- -	- -
Free Cash Flow	-3	-4	-19	-12	-11
Free Cash Flow to Firm	- -	- -	- -	- -	- -
Free Cash Flow to Equity	- -	-5	-19	-12	-11
Free Cash Flow per Basic Share	-119.25	-81.05	-234.77	-121.25	-28.81
Price/Free Cash Flow	-5.39	-12.8	-6.31	-0.53	-0.14
Cash Flow to Net Income	0.13	0.36	0.95	0.31	0.55

180 Life Sciences Corp.

Income Statement

Balance Sheet

Cash Flow Statement